Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

NCT05440942 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Trametinib
DRUG: Ruxolitinib
DRUG: Retifanlimab

Sponsor

Peter Hosein, MD

Collaborators

[object Object]
[object Object]
[object Object]